Maxxon Signs Safety Syringe Development Agreement With Genesis Design
Group
TULSA, Okla., May 2, 2000 (BW HealthWire) -- Maxxon, Inc. (OTCBB:MXON) announced
today the execution of an exclusive Product Development Agreement with Genesis
Design Group of Simi Valley, California, which provides for the design,
engineering, computer modeling, verification and prototyping of Maxxon's new
Safety Syringe.
Maxxon recently acquired the exclusive worldwide rights to manufacture and
market a novel proprietary safety syringe invented and developed by Mr. Wayland
J. Rippstein, a retired NASA scientist. The syringe is a single-hand-operated,
one-use vacuum safety syringe that retracts the contaminated needle into the
barrel after use. The vacuum is created at the time of the injection and not at
the time of manufacture, thus providing long shelf life.
The Genesis Design Group is an industry leader in product development services
with expertise in industrial design, engineering, analysis, 3D solid modeling
and computer animation. The group expects to provide Maxxon with a prototype
built to production specifications, complete with stereolithography parts for
design verification, in 6-8 weeks. Mr Rippstein will be involved on behalf of
Maxxon in all phases of the Genesis endeavor and will remain actively and
directly involved with Genesis through the development of prototypes and
commencement of manufacturing.
Mr. Rippstein retired in 1983 from NASA as the Head of the Toxicology
Laboratory, where he worked extensively with syringes, vacuums and other
problems on the cutting edge of technology for more than 20 years. Since his
retirement, Mr. Rippstein has been a consultant to various businesses. He has
testified extensively as an expert witness in litigation involving the
toxicological chemical effects of fires, explosions and other catastrophic
events. Mr. Rippstein also owned and operated a chemical manufacturing firm for
more than 7 years, selling primarily agricultural chemicals. He is a graduate of
the University of Texas with a master's degree in Chemistry.
Maxxon is a development stage company which has been refining a single-handed
vacuum operated safety syringe for more than 2 years. Maxxon's objective is to
help prevent accidental needlestick injuries and deaths to healthcare workers
caused by unprotected, used needles.
For more information, please contact:
Morgan-Phillips, Inc. (800) 770-4856 (918) 250-8028 www.Morgan-Phillips.com
This press release contains some forward-looking statements. We undertake no
obligation to publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise. Forward-looking statements in
this document should be evaluated together with the many uncertainties that
affect our business. Those uncertainties are discussed in the Company's SEC
filings.
Distributed via COMTEX.
Copyright (C) 2000 Business Wire. All rights reserved.
-0-
CONTACT: Morgan-Phillips, Inc.
(800) 770-4856
(918) 250-8028
www.Morgan-Phillips.com
bcjt |
